Chien‐Chin Lin

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini et al. · The Lancet · 2023 · 154 citations · Full text

Hematological Malignancy, Thrombosis, Interim Analysis +12

Genetic alterations and their clinical implications in older patients with acute myeloid leukemia

Cheng‐Hong Tsai, Hsin‐An Hou, Jih‐Luh Tang et al. · Leukemia · 2016 · 108 citations

Hematological Malignancy, Older Patients, Medicine +12

Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia

Hsin‐An Hou, Chien‐Chin Lin, Wen‐Chien Chou et al. · Leukemia · 2013 · 93 citations · Full text

Hematological Malignancy, Oncology, Medicine +12

<i>IDH</i> mutations are closely associated with mutations of <i>DNMT3A</i>, <i>ASXL1</i> and <i>SRSF2</i> in patients with myelodysplastic syndromes and are stable during disease evolution

Chien‐Chin Lin, Hsin‐An Hou, Wen‐Chien Chou et al. · American Journal of Hematology · 2013 · 82 citations · Full text

Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome

Hsin‐An Hou, Cheng‐Hong Tsai, Chien‐Chin Lin et al. · Blood Cancer Journal · 2018 · 82 citations · Full text